[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Joseph Klein III, a director of Ionis Pharmaceuticals, reported multiple transactions dated 09/03/2025. The filing shows two non-derivative acquisitions recorded as 16,000 and 12,000 shares of common stock reported with transaction code M and price listed as $0.0, each noted as indirectly owned by a trust. On the same date the form records a sale of 28,000 common shares at $60 per share, with an explanatory note stating the sale was made pursuant to a Rule 10b5-1 trading plan adopted January 3, 2024. The report also lists 16,346 shares held directly and 100 shares held indirectly by his son, with the filer disclaiming beneficial ownership of the son's shares.
Joseph Klein III, amministratore di Ionis Pharmaceuticals, ha segnalato più operazioni in data 09/03/2025. La comunicazione riporta due acquisizioni non derivate di 16.000 e 12.000 azioni ordinarie, indicate con il codice transazione M e prezzo pari a $0.0, entrambe indirettamente possedute da un trust. Nella stessa data il modulo registra la vendita di 28.000 azioni ordinarie a $60 ciascuna; la nota esplicativa specifica che la vendita è avvenuta in base a un piano di negoziazione Rule 10b5-1 adottato il 3 gennaio 2024. Il rapporto indica inoltre 16.346 azioni detenute direttamente e 100 azioni detenute indirettamente da suo figlio, con il dichiarante che nega la titolarità beneficiaria delle azioni del figlio.
Joseph Klein III, director de Ionis Pharmaceuticals, informó varias transacciones con fecha 09/03/2025. El informe muestra dos adquisiciones no derivadas de 16.000 y 12.000 acciones ordinarias, registradas con el código de transacción M y precio de $0.0, ambas poseídas indirectamente por un fideicomiso. Ese mismo día se registra la venta de 28.000 acciones ordinarias a $60 por acción; la nota aclara que la venta se realizó conforme a un plan de negociación Rule 10b5-1 adoptado el 3 de enero de 2024. El informe también señala 16.346 acciones en posesión directa y 100 acciones poseídas indirectamente por su hijo, y el declarante niega la propiedad beneficiaria de las acciones del hijo.
Joseph Klein III, Ionis Pharmaceuticals의 이사, 은 2025-09-03자로 여러 거래를 보고했습니다. 제출서류에는 거래 코드 M과 가격 $0.0로 기재된 보통주 16,000주와 12,000주의 비파생 취득이 각각 신탁을 통해 간접 보유된 것으로 표시되어 있습니다. 같은 날짜에 양식에는 보통주 28,000주를 주당 $60에 매각한 기록이 있으며, 해당 매각은 2024년 1월 3일 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌다는 설명이 붙어 있습니다. 보고서에는 또한 직접 보유한 16,346주와 아들이 간접 보유한 100주가 기재되어 있고, 신고인은 아들의 주식에 대한 실질적 소유권을 부인하고 있습니다.
Joseph Klein III, administrateur d'Ionis Pharmaceuticals, a déclaré plusieurs opérations datées du 09/03/2025. Le dossier fait état de deux acquisitions non dérivées de 16 000 et 12 000 actions ordinaires, enregistrées avec le code de transaction M et un prix de $0.0, toutes deux détenues indirectement par une fiducie. À la même date, le formulaire mentionne la vente de 28 000 actions ordinaires au prix de $60 par action ; la note explicative précise que la vente a été effectuée conformément à un plan de négociation Rule 10b5-1 adopté le 3 janvier 2024. Le rapport indique également 16 346 actions détenues directement et 100 actions détenues indirectement par son fils, le déclarant déclinant la qualité de bénéficiaire des actions détenues par son fils.
Joseph Klein III, Direktor von Ionis Pharmaceuticals, meldete mehrere Transaktionen datiert 09.03.2025. Die Einreichung weist zwei nicht-derivative Erwerbe von 16.000 bzw. 12.000 Stammaktien aus, aufgeführt mit dem Transaktionscode M und einem Preis von $0.0, jeweils indirekt durch einen Trust gehalten. Am selben Datum verzeichnet das Formular den Verkauf von 28.000 Stammaktien zu $60 je Aktie; eine Erläuterung weist darauf hin, dass der Verkauf im Rahmen eines am 3. Januar 2024 verabschiedeten Rule 10b5-1 Trading Plans erfolgte. Der Bericht listet außerdem 16.346 direkt gehaltene Aktien und 100 Aktien, die indirekt von seinem Sohn gehalten werden, wobei der Einreicher jegliches wirtschaftliches Eigentum an den Aktien des Sohnes verneint.
- Sale executed under a Rule 10b5-1 trading plan, which provides an affirmative defense and signals pre-planned execution
- Timely Section 16 disclosure by the reporting person showing compliance with insider reporting rules
- Clear disclaimer disavowing beneficial ownership of securities held by the reporting person's son
- Insider sale of 28,000 shares at $60 represents a notable disposition of shares by a director
- Acquisitions reported at $0.0 and option-related entries may indicate complex internal transfers that reduce transparency for some investors
Insights
TL;DR: Director executed planned sale under a 10b5-1 plan; additional trust-related movements reported.
The Form 4 documents transparent disclosure of insider activity: a sale of 28,000 shares at $60 executed under a Rule 10b5-1 plan, which typically provides an affirmative defense against insider trading claims when properly adopted. Concurrently, the report shows acquisitions of 16,000 and 12,000 shares recorded as indirect trust holdings at $0.0, and the filing includes a disclaimer of beneficial ownership for 100 shares held by the reporting person’s son. From a governance perspective, the filing demonstrates compliance with Section 16 reporting and use of a trading plan to manage potential conflicts.
TL;DR: Insider sold 28,000 shares at $60 and reported trust-related option exercises or transfers; net beneficial holdings remain small relative to corporate scale.
The key market-impacting item is the disclosed sale of 28,000 shares at $60 per share executed pursuant to a 10b5-1 plan. The form also records two M-coded acquisitions totaling 28,000 common shares (16,000 and 12,000) listed at $0.0 and two non-qualified stock option exercises reported in Table II that correspond to those amounts. The report ends with 16,346 shares listed as directly owned and a 100-share indirect position tied to a family member. These transactions are routine insider activity and, absent additional context about total outstanding shares or larger holdings, do not by themselves indicate a material change to ownership control.
Joseph Klein III, amministratore di Ionis Pharmaceuticals, ha segnalato più operazioni in data 09/03/2025. La comunicazione riporta due acquisizioni non derivate di 16.000 e 12.000 azioni ordinarie, indicate con il codice transazione M e prezzo pari a $0.0, entrambe indirettamente possedute da un trust. Nella stessa data il modulo registra la vendita di 28.000 azioni ordinarie a $60 ciascuna; la nota esplicativa specifica che la vendita è avvenuta in base a un piano di negoziazione Rule 10b5-1 adottato il 3 gennaio 2024. Il rapporto indica inoltre 16.346 azioni detenute direttamente e 100 azioni detenute indirettamente da suo figlio, con il dichiarante che nega la titolarità beneficiaria delle azioni del figlio.
Joseph Klein III, director de Ionis Pharmaceuticals, informó varias transacciones con fecha 09/03/2025. El informe muestra dos adquisiciones no derivadas de 16.000 y 12.000 acciones ordinarias, registradas con el código de transacción M y precio de $0.0, ambas poseídas indirectamente por un fideicomiso. Ese mismo día se registra la venta de 28.000 acciones ordinarias a $60 por acción; la nota aclara que la venta se realizó conforme a un plan de negociación Rule 10b5-1 adoptado el 3 de enero de 2024. El informe también señala 16.346 acciones en posesión directa y 100 acciones poseídas indirectamente por su hijo, y el declarante niega la propiedad beneficiaria de las acciones del hijo.
Joseph Klein III, Ionis Pharmaceuticals의 이사, 은 2025-09-03자로 여러 거래를 보고했습니다. 제출서류에는 거래 코드 M과 가격 $0.0로 기재된 보통주 16,000주와 12,000주의 비파생 취득이 각각 신탁을 통해 간접 보유된 것으로 표시되어 있습니다. 같은 날짜에 양식에는 보통주 28,000주를 주당 $60에 매각한 기록이 있으며, 해당 매각은 2024년 1월 3일 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌다는 설명이 붙어 있습니다. 보고서에는 또한 직접 보유한 16,346주와 아들이 간접 보유한 100주가 기재되어 있고, 신고인은 아들의 주식에 대한 실질적 소유권을 부인하고 있습니다.
Joseph Klein III, administrateur d'Ionis Pharmaceuticals, a déclaré plusieurs opérations datées du 09/03/2025. Le dossier fait état de deux acquisitions non dérivées de 16 000 et 12 000 actions ordinaires, enregistrées avec le code de transaction M et un prix de $0.0, toutes deux détenues indirectement par une fiducie. À la même date, le formulaire mentionne la vente de 28 000 actions ordinaires au prix de $60 par action ; la note explicative précise que la vente a été effectuée conformément à un plan de négociation Rule 10b5-1 adopté le 3 janvier 2024. Le rapport indique également 16 346 actions détenues directement et 100 actions détenues indirectement par son fils, le déclarant déclinant la qualité de bénéficiaire des actions détenues par son fils.
Joseph Klein III, Direktor von Ionis Pharmaceuticals, meldete mehrere Transaktionen datiert 09.03.2025. Die Einreichung weist zwei nicht-derivative Erwerbe von 16.000 bzw. 12.000 Stammaktien aus, aufgeführt mit dem Transaktionscode M und einem Preis von $0.0, jeweils indirekt durch einen Trust gehalten. Am selben Datum verzeichnet das Formular den Verkauf von 28.000 Stammaktien zu $60 je Aktie; eine Erläuterung weist darauf hin, dass der Verkauf im Rahmen eines am 3. Januar 2024 verabschiedeten Rule 10b5-1 Trading Plans erfolgte. Der Bericht listet außerdem 16.346 direkt gehaltene Aktien und 100 Aktien, die indirekt von seinem Sohn gehalten werden, wobei der Einreicher jegliches wirtschaftliches Eigentum an den Aktien des Sohnes verneint.
FAQ
What did Joseph Klein III report on the Form 4 for IONS?
Was the 28,000-share sale by Joseph Klein III part of a preplanned program?
Are any securities listed as held by family members in the Form 4?
Do the acquisitions show a purchase price?
Who signed the Form 4 on behalf of Joseph Klein III?
